A fixed duration combination of venetoclax with acalabrutinib, with or without obinutuzumab, was superior to standard ...
Sanofi reports positive Phase III results for its BTK inhibitor in treating immune thrombocytopenia, demonstrating faster ...
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tolebrutinib for the treatment of ...
BTIG initiated coverage of Nurix Therapeutics (NRIX) with a Buy rating and $35 price target Nurix is a protein degrader company whose lead ...
Sanofi has presented promising results from a phase 3 study of its investigational oral Bruton’s tyrosine kinase (BTK) ...
Everest Medicines has announced promising results from the Phase 1b/2a clinical trial of EVER001, a novel Bruton’s tyrosine ...
Medpage Today on MSN6d
Novel BTK Inhibitor Succeeds in Heavily Pretreated Immune ThrombocytopeniaSAN DIEGO -- Treatment with an investigational oral inhibitor of Bruton's tyrosine kinase (BTK) was safe and boosted platelet ...
Eli Lilly (LLY) and Company announced results from the Phase 3 BRUIN CLL-321 trial evaluating pirtobrutinib, a non-covalent Bruton’s tyrosine ...
As reported by the South China Morning Post today, Everest Medicines (HKEX 1952.HK) is accelerating its journey to become a leading bi ...
ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP Pivotal phase 3 data show rapid and durable platelet response, reduced ...
Data from the Phase I/II TRANSCEND CLL 004 study evaluating the combination of Bristol Myers Squibb’s (BMS’s) Breyanzi ...
Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback